Charles River

Charles River taking advantage of biotech growth, CEO says

Charles River taking advantage of biotech growth, CEO says

By Zachary Brennan

For the first time ever, Charles River Laboratories is seeing its biotech revenues eclipse its pharma revenues, Jim Foster, chairman, president and CEO of CRL, told participants at the Baird Growth Stock Conference last week.

CRL pushes deeper into an increasingly lucrative Asia

Charles River expands presence in Asia with acquisition

By Zachary Brennan

Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers